Advertorial: Next-generation microbial testing of pharmaceuticals

Specialised microbial testing is key in drug development to mitigate contamination risks, which threaten drug efficacy and patient safety. Bruker’s MALDI Biotyper® at MPL, Austria, ensures accurate and robust testing, in a high-throughput workflow, delivering reproducible results.

 Next-generation microbial testing of pharmaceuticals

The trend towards outsourcing is showing no sign of abating in the pharmaceutical and biopharmaceutical industries, with organisations of all sizes relying on the expertise of specialist service partners to reduce overheads, benefit from experts in service labs, minimise in-house performance risk for routine microbial monitoring, and accelerate the process of bringing new drugs to market.

This is confirmed by a recent survey, which reports a 50 percent likelihood of outsourcing pre- and post-approval safety analysis in the next two years.1 Set this against the backdrop of rising new drug development times pushing costs to a staggering $2.3 billion between 2021 and 2022 alone,2 and it is clear that safety and speed hold the key to more effective drug development.